Abstract A series of b-benzoylstyrene derivatives of acridine (4a-r) have been synthesized and characterized using IR, 1 H NMR and Mass Spectroscopy. All the compounds were screened for intraerythrocytic in vitro antimalarial activity against Chloroquine-sensitive (3D7) & Chloroquine-resistant (Dd2) strains of Plasmodium falciparum using the SYBR Green I fluorescence assay. Cytotoxicity study was performed against the HeLa cell line using the MTT assay. Compounds 4c, 4d, and 4l are most potent with IC 50 in the range of 0.30-0.52 lM against the 3D7 strain and 0.15-0.32 lM against the Dd2 strain. The results revealed that antimalarial potency and good resistance indices were not at the cost of safety since the most potent compounds have turned out to have promising therapeutic indices in the range of 80-520. 
Introduction
Malaria is an important cause of death and illness in children and adults, especially in tropical countries. World Health Organization estimates that half of the world's population is at risk of malaria. Globally, 300-500 million episodes of malarial illnesses occur each year, resulting in over one million deaths from this devastating disease (Lou, et al., 2001; Hay, et al., 2004) . Chloroquine (CQ) (Fig. 1a) and other quinoline antimalarials such as Amodiaquine (Fig. 1b) and Mefloquine ( Fig. 1c) have been the mainstays of malaria chemotherapy for the past five decades because of excellent clinical efficacy, limited host toxicity, ease of use and simple cost-effective synthesis. Unfortunately the efficacy of quinoline based antimalarial is eroded by the emergence of resistant parasites (Foley and Tilley, 1998) . The development of drug resistance has become a major health concern and has stimulated the search for alternative antimalarial agents. In this perspective the acridine nucleus offers an alternative to quinoline moiety. Indeed Quin-acrine ( Fig. 1d) an acridine, was the first synthetic antimalarial used even before Chloroquine (Bruce-Chwatt, 1964) . Pyronaridine (Fig. 1e ), a new acridine based antimalarial developed in China is effective against Chloroquine resistant strain of Plasmodium falciparum (Chang, et al., 1992) . Acridine derivatives containing 9-aminoacridine and 9-anilinoacridine scaffolds have been reported to exhibit antimalarial activity (Obexer, et al., 1995; Girault, et al., 2000; Chibale, et al., 2001; Santelli-Rouvier, et al., 2004; Guetzoyan, et al., 2009; Kumar, et al., 2009) . In general, the acridine moiety has been found to possess diverse biological attributes including antitumor, (Baguley, et al., 1981) antiprion, (May, et al., 2006) anti-alzheimer, (Fang, et al., 2008) antileishmanial and antitrypanosomal (Gamage, et al., 1994) activities. Various modes of action of acridine derivatives for their antimalarial effect have been proposed including DNA intercalation, (Chen, et al., 1978) binding to heme, (Dorn, et al., 1998) and inhibition of the enzyme topoisomerase II (Gamage, et al., 1994) .
Here we report the synthesis, characterization and antimalarial activity together with resistance and therapeutic indices of eighteen (4a-r) new b-benzoylstyrene derivatives of acridine.
Materials and methods
Melting points were determined in a Thomas micro hot stage apparatus and are uncorrected. The progress of the reactions was monitored by thin layer chromatography (TLC) with ethyl acetate: hexane (1:1 v/v) as eluent. All solvents were dried and TLC was carried out on precoated plates (silica gel 60, F254) and visualized with UV light. Column chromatography was performed on silica gel A mixture of 2,4-dichlorobenzoic acid (7.68 g, 40.2 mmol) and p-anisidine (9.8 g, 79.6 mmol, potassium carbonate (6.9 g, 50.0 mmol) and Cu-powder (40 mesh, 0.24 g, 3 wt.% with respect to the amount of benzoic acid used) was heated in amyl alcohol (40 mL) containing pyridine (1.21 g, 15 wt.%) for 5 h under reflux. After cooling to room temperature, the solution was acidified with hydrochloric acid and the crude product was filtered off and recrystallized from ethanol to afford the product. Yield 55%; m.p.; 206-208°C; IR (KBr) cm À1 ; 3321 (N-H), 3008 (C-H), 2954 (OH), 2833, 1662 (C‚O), 1596, 1570, 1515, 1460, 1426, 1334, 1250, 1232, 1178,1156, 1102, 2.1.2. Synthesis of the substituted 6,9-dichloro-2-methoxy acridine (2)
4-Chloro-2-(4-methoxyanilino) benzoic acid (6.7 mmol) was dissolved in POCl 3 (15 mL) and heated under reflux for 6 h. After cooling to room temperature the reaction mixture was poured very carefully under vigorous stirring into a mixture containing crushed ice (200 g), ammonia (100 mL) and chloro- Synthesis, characterization and antimalarial evaluation of new b-benzoylstyrene derivatives of acridine S275 form (250 mL) keeping the pH during this operation always >8. The phases were separated and the aqueous phase was extracted with chloroform (2 · 100 mL), the organic phases were combined, dried (CaCl 2 ) and evaporated to yield the crude product that was pure enough for further transformations. 2.1.3. Synthesis of 1-(4-(6-chloro-2-methoxyacridin-9-ylamino) phenyl) ethanone (3) A mixture of 4-aminoacetophenone (0.4 g, 0.003 mol) and 6,9-dichloro-2-methoxyacridine (0.83 g, 0.003 mol) was dissolved in ethanol. Few drops of HCI were added to the reaction mixture to catalyze the reaction. The content was refluxed for 8 h. 2.1.4. General procedure for the synthesis of compounds (4a-r) 1-(4-(6-chloro-2-methoxyacridin-9-ylamino) phenyl) ethanone (1 mmol), substituted aldehydes (1 mmol) and 2.5 mmol of pulverized sodium hydroxide were dissolved in dry methanol (5 mL). The reaction mixture was stirred at room temperature for 8-12 h, the resulting precipitates were filtered off and recrystallized in ethanol, yields 25-89%.
2.1.4.1.
(E)-1-(4-(6-chloro-2-methoxyacridin-9-ylamino)phenyl)-3-phenylprop-2-en-1-one (4a). Orange crystal; Yield 339.4 mg (73%); m.p.; 256°C; IR (KBr) cm À1 3325.8 (N-H), 3096.8 (C-H), 1715.8 (C‚O), 1683.5 (C‚C), 1505.9 (C‚N), 1314.7, 1264.5, 1304.7 (C-N) 
2.1.4.3.
(E)-1-(4-(6-chloro-2-methoxyacridin-9-ylamino)phenyl)-3-(2-nitrophenyl) prop-2-en-1-one (4c). Orange crystal; Yield 316.2 mg (62%); m.p.; 246°C; IR (KBr) cm 
2.1.4.4.
(E)-1-(4-(6-chloro-2-methoxyacridin-9-ylamino)phenyl)-3-(2-methoxyphenyl) prop-2-en-1-one (4d (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylamino)phenyl)-3-(3-nitrophenyl) prop-2-en-1-one (4f (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylamino)phenyl)-3-(3-methoxyphenyl) prop-2-en-1-one (4g 2.1.4.8. 2.1.4.9.
(E)-1-(4-(6-chloro-2-methoxyacridin-9-ylamino)phenyl)-3-(3, 4-dimethoxyphenyl) prop-2-en-1-one (4i (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylamino)phenyl)-3-(4-chlorophenyl) prop-2-en-1-one (4j). Orange crystal; Yield 329.6 mg (66%); m.p.; 248°C; IR (KBr) cm 2.1.4.12.
(E)-1-(4-(6-chloro-2-methoxyacridin-9-ylamino)phenyl)-3-(4-methoxyphenyl) prop-2-en-1-one (4l). Orange crystal; Yield 346.5 mg (70%); m.p.; 215°C; IR (KBr) cm 
2.1.4.13.
(E)-1-(4-(6-chloro-2-methoxyacridin-9-ylamino)phenyl)-3-(4-hydroxyphenyl) prop-2-en-1-one (4m 2.1.4.14.
(E)-1-(4-(6-chloro-2-methoxyacridin-9-ylamino)phenyl)-3-p-tolyprop-2-en-1-one (4n 
2.1.4.15.
(E)-1-(4-(6-chloro-2-methoxyacridin-9-ylamino)phenyl)-3-(4-ethylphenyl) prop-2-en-1-one (4o). Orange crystal; Yield 315.5 mg (64%); m.p.; 232°C; IR (KBr) cm (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylamino)phenyl)-3-(4-(dimethylamino)phenyl)
prop-2-en-1-one (4p). Orange crystal; Yield 376 mg (74%) (E)-4-(3-(4-(6-chloro-2-methoxyacridin-9-ylamino)phenyl)-3-oxoprop-1enyl) benzonitrile (4q (E)-1-(4-(6-chloro-2-methoxyacridin-9-ylamino)phenyl)-3-(4-fluorophenyl) prop-2-en-1-one (4r 
Antimalarial evaluation

Measurement of inhibition of P. falciparum growth in culture
In this study chloroquine sensitive 3D7 and Chloroquine resistant Dd2 strains provided by MR4/ATCC (Manassas, USA) were used in in vitro culture. Parasite strains were cultivated by the method of Trager and Jensen (1976) with minor modifications (Trager and Jensen, 1976) . Cultures were maintained in fresh O + human erythrocytes at 4% hematocrit in complete medium [RPMI 1640 (supplemented with 25 mM HEPES and L-Glutamine) with 0.2% sodium bicarbonate 0.5% Albumax, 45 mg/L hypoxanthine and 50 mg/L gentamicin] at 37°C under reduced O 2 (gas mixture 5% O 2 , 5% CO 2 , and 90% N 2 ). Stock solutions of Chloroquine (CQ) were prepared in water (miliQ grade) and test compounds were dissolved in DMSO. All stocks were then diluted with Complete culture medium to achieve the required concentrations (In all cases the final concentration contained 0.4% DMSO, which was found to be non-toxic to the parasite). CQ and test compounds were then placed in 96-well flat-bottomed tissue culture grade plates to yield triplicate wells with drug concentrations ranging from 0 to 10 À4 M in a final well volume of 100 ll for primary screening. Chloroquine was used as a positive control in all experiments. Parasite culture was synchronized at the ring stage with 5% sorbitol. Synchronized culture was aliquoted to drug containing a 96-well plate at 2% hematocrit and 1% parasitemia. After 48 h of incubation under standard culture conditions, plates were harvested by the addition of SYBR Green I containing lysis buffer (100 ll) and read by the SYBR Green I fluorescence-based method (Smilkstein et al. 2004 ) using a 96-well fluorescence plate reader (Victor, Perkin Elmer), with excitation and emission wavelengths at 497 and 520 nm, respectively. The fluorescence readings were plotted against drug concentration, and IC 50 values obtained by visual matching of the drug concentration giving 50% inhibition of growth.
Measurement of cytotoxic activity against mammalian cell lines in culture
Animal cell line (Hela) was used to determine drug toxicity by using MTT assay for mammalian cell viability assay as described by Mosmann 1983 . Hela cells cultured in complete RPMI (cRPMI) containing 10% fetal bovine serum, 0.2% sodium bicarbonate, 50 mg/L gentamycin. Briefly, Cells (10 4 cells/200 ll/well) were seeded into 96-well flat-bottomed tissue-culture plates in a complete culture medium. Drug solutions were added after overnight seeding and incubated for 24 h in a humidified atmosphere at 37°C and 5% CO 2 . DMSO (final concentration 10%) was added as +ve control. An aliquot of a stock solution of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) (5 mg/mL in 1X phosphate-buffered saline) was added at 20 ll per well, and incubated for another 3 h. After spinning the plate at 1500 RPM for 5 min, supernatant was removed and 100 ll of the stop agent DMSO was added to the well to dissolve the formazan crystals. Formation of formazon, an index of growth was read at 570 nm by a 96-well plate reader (Versa Max) and IC 50 values were determined by analysis of dose-response curves. Therapeutic index was calculated as IC 50 Mammalian cell/ IC 50 Pf3D7.
Results and discussion
Chemistry
The synthetic pathway for b-benzoylstyrene derivatives of acridine (4a-r) is illustrated in Scheme 1. Compound 4-chloro-2-(4-methoxyanilino) benzoic acid (1) was prepared by performing Ullmann condensation between 2,4-dichlorobenzoic acid and p-anisidine. Subsequently the refluxing of 4-Chloro-2-(4-methoxyanilino) benzoic acid in phosphorus oxychloride resulted in the formation of 6,9-dichloro-2-methoxyacridine (2) (Csuk, et al., 2004) . Condensation of 6,9-dichloro-2-methoxyacridine and 4-aminoacetophenone afforded 1-(4-(6-chloro-2-methoxyacridin-9-ylamino) phenyl) ethanone (3) (Aly and Abadi, 2004) . Compound 1-(4-(6-chloro-2-methoxy acridin-9-ylamino)phenyl) ethanone was reacted with a series of substituted aromatic aldehydes to obtain b-benzoylstyrene derivatives of acridine (4a-r) ( Table 1 ). All compounds synthesized as above have been characterized by spectral data (IR, 1 H NMR, Mass).
Antimalarial activity
All the synthesized compounds were evaluated for their antimalarial activity against CQ-sensitive (3D7) as well as CQresistant (Dd2) strains of P. falciparum through in vitro red blood cell based culture using SYBR-Green-I assay (Smilkstein et al., 2004) . The results of antimalarial potencies are summarized in Table 1 . Variations of different substituents on the aromatic ring of b-benzoylstyrene derivatives of acridine have been explored to ascertain the structure-activity relationship among the synthesized compounds of the series. Among the eighteen evaluated compounds of the series against CQ-sensitive (3D7), three compounds (4c, 4d, 4l) were most potent and showed antimalarial IC 50 values in the range of 0.30-0.52 lM. Six compounds (4a, 4b, 4f, 4j, 4k, and 4m) displayed antimalarial activity in the range 0.7-1.5 lM. Nine compounds (4e, 4g, 4h, 4i, 4n, 4o, 4p, 4q and 4r) exhibited the IC 50 values ranging from 1.6-4.8 lM. However, activity results clearly suggest that among the monomethoxy substituted compounds (4d, 4g, 4l), the 4-substituted methoxy compound 4l is the most potent (IC 50 = 0.3 lM). Indeed compound 4l is six times more active than its 3-methoxy counterpart (compound 4g, IC 50 = 1.8 lM) whereas the 2-methoxy substitution (4d, IC 50 : 0.52 lM) results in a slight decrease in activity. Additional methoxy group at position-3 (4i, 3,4-dimethoxy) leads to a significant fall in activity (IC 50 = 4.0 lM).
Isomeric compounds 4c (2-nitro, IC 50 : 0.35 lM), 4f (3-nitro, IC 50 : 1.3 lM) and 4k (4-nitro, IC 50 : 0.7 lM) suggest that positional isomerism of the Nitro group on the aromatic ring of b-benzoylstyrene can cause subtle changes in potency. It was interesting to see over fivefold increase in activity ongoing from compound 4e (2-hydroxy, IC 50 : 4.5 lM) to compound 4m (4-hydroxy, IC 50 : 0.8 lM). The 3, 4-dihyroxy compound 5 (IC 50 : 2 lM) although less active than compound 4m (4-hydroxy, IC 50 : 0.8 lM) is nevertheless more active than compound 4e (2-hydroxy, IC 50 : 4.5 lM). With reference to the unsubstituted compound 4a (IC 50 : 0.75 lM) substitution with methoxy (compound 4d, IC 50 : 0.52 lM) or nitro (compound 4c, IC 50 : 0.35 lM) appeared to potentiate antimalarial activity while substitutions by hydroxyl (compound 4e, IC 50 : 4.5 lM) or chlorine (compound 4b, IC 50 : 1.5 lM) brought about a reduction in potency.
The two substitutions at position-3 (methoxy compound 4g, Nitro compound 4f) indicate that these substitutions lead to marginal decrease in potency in comparison with the unsubstituted compound 4a. The compounds 4c and 4l were found to be nearly equipotent against both Chloroquine sensitive 3D7 and Chloroquine resistant Dd2 strains, giving resistance indices in the range of 0.88-1. Interestingly compounds 4b, 4d, 4f, 4g, 4h, 4j, 4n, 4o and 4r were found to be more potent against the Chloroquine resistant Dd2 strain than the Chloroquine sensitive 3D7 strain resulting in resistance indices in the range of 0.15-0.7. All the synthesized compounds were further evaluated for Cytotoxicity by MTT assay (Mosmann, 1983) against HeLa cell line. Interestingly, as shown in Table 1 , all the compounds evaluated showed good selectivity indices in the range of 20-520. The compounds 4c, 4d, 4l were the most potent against malarial parasites also exhibited high selectivity indices in the range of 80-520.
Conclusion
In conclusion, there is challenge and urgency to synthesize cost effective highly potent and less toxic chemotherapeutic agents for the treatment of malaria after the widespread development of resistance to chloroquine. As part of our research a series of eighteen b-benzoylstyrene derivatives of acridine, were synthesized and examined for in vitro antimalarial activity. Compounds 4c, 4d and 4l exhibited very good antimalarial activity with high selectivity and promising resistance indices. Further exploration and optimization of b-benzoylstyrene derivatives of acridine could provide novel antimalarial molecules which can eradicate issues of cross resistance to drugs like Chloroquine.
